Germany - Drugs

Description

Conclusion of drug discount agreements in accordance with Section 130a (8) SGB V
Granisetron; 1 supplement fosaprepitant; 1 supplement metformin and vildagliptin; 1 supplement vildagliptin; 1 supplement miglustat; 3 supplements ambrisentan; 1 supplement chlortalidone; 1 supplement enalapril maleate and lercanidipine hydrochloride; 3 supplements enalapril maleate and lercanidipine hydrochloride; 1 supplement amlodipine and ramipril; 1 supplement olmesartan medoxomil; 3 supplements olmesartan medoxomil and hydrochloro-thiazide; 1 supplement amlodipine and telmisartan; 1 supplement olmesartan medoxomil and amlodipine and hydrochlorothiazide; 3 supplements colesevelam hydrochloride; 1 supplement ezetimibe and simvastatin; 3 supplements tibolone; 1 supplement raloxifene hydrochloride; 1 supplement tolterodine (R,R)-tartrate; 1 supplement trospium chloride; 1 supplement octreotide; 1 supplement potassium iodide; 1 supplement ceftriaxone; 1 supplement voriconazole; 1 supplement zidovudine and lamivudine; 1 supplement bexarotene; 1 supplement methotrexate; 1 supplement methotrexate; 3 supplements pirfenidone; 3 supplements dimethyl fumarate; 2 supplements dimethyl fumarate; 1 supplement ibandronic acid; 1 supplement ibandronic acid; 3 supplements tapentadol; 2 supplements tapentadol; 1 supplement ropinirole; 1 supplement quetiapine; 3 supplements paliperidone; 1 supplement tianeptine sodium; 1 supplement rivastigmine; 3 supplements rivastigmine; 1 supplement naltrexone hydrochloride; 1 supplement amifampridine; 1 supplement beclometasone dipropionate; 1 supplement montelukast; 3 supplements montelukast; 1 supplement rupatadine; 1 supplement bimatoprost; 1 supplement

Opportunity closing date

16 March 2023

Value of contract

to be confirmed